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Delirium is associated with increased mortality and hospital length of stay. Limited data are 
available from HIV-infected acute hospital admissions in developing countries. We 
conducted a prospective study of delirium amongst acute medical admissions in South Africa 




Three cohorts of adult acute medical admissions to Groote Schuur and Victoria Hospitals, 
Cape Town, South Africa were evaluated for prevalent delirium within 24 hours of 
admission. Reference delirium testing was performed by either consultant physicians or 
neuropsychologists, using the Confusion Assessment Method (CAM).  
 
Findings 
The study included 1182 acute medical admissions; with 318 (26·9%) HIV-infected 
Median(IQR) age and CD4 count was 35(30-43) years and 132(61-256) cells/mm3 
respectively, with 140/318(44%) using ART on admission. Delirium prevalence was 
17·6%(95% CI 13·7-22·1%) amongst HIV-infected patients and was an independent risk 
factor for inpatient mortality. In multivariable logistic regression, factors associated with 
delirium were age ≥55 years(AOR 6·95[2·03-23·67], p=0·002) and urea ≥15(AOR 4·83[1·7-
13·44], p=0·003), while ART use reduced risk (p=0·014). Low CD4 count, unsuppressed 
viral load, and active TB were not predictors of delirium; nor were other traditional risk 






Delirium is common and predicts poor outcome in HIV-infected acute medical admissions in 
endemic settings despite increased ART use. Older HIV-infected patients with renal 
dysfunction are at high risk for inpatient delirium while those using ART on admission are 
protected.  
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Delirium is a heterogeneous, fluctuating syndrome of acute brain failure.(1) Patients with 
delirium have deranged attention, orientation, cognition, and sleep-wake cycles, as well as 
psychomotor and behavioural problems.(2-5) Delirium is often viewed as a complication of 
in-patient care and a marker of the quality of care.(6) Current literature generally focuses on 
studies in developed countries within geriatric and intensive care populations. The prevalence 
of delirium is variable, with rates of 10-31% in medical inpatients, 40% in nursing homes, 
and up to 80% in ICU settings.(7, 8) This common disorder has significant long term and 
short term complications, and a high mortality rate.(6)  
 
Delirium pathophysiology 
The pathophysiology of delirium has not been clearly defined. The clinical presentation of 
delirium may represent Central Nervous System (CNS) reactions to central or peripheral 
stressors, with interaction between central and peripheral pathways. There are multiple 
hypotheses regarding the pathophysiology of delirium, but these theories can be broadly 
separated into: Neurotransmitter hypothesis and Immune-inflammation dysregulation. 
 
Neurotransmitter hypothesis  
In the neurotransmitter hypothesis precipitating events lead to oxidative stress in the CNS and 
changes in concentration of various neurotransmitters. This theory arises from the 




neurotransmitters (e.g. anti-cholinergic drugs and dopamine agonists).(9, 10) Underactivity of 
the cholinergic system and excess release of dopamine, norepinephrine, and glutamate with 
both increased/decreased serotonergic and gamma-aminobutyric acid activity may be risk 
factors for delirium.(9-14) 
 
The Immune-inflammation dysregulation theory 
The Immune-inflammation dysregulation theory draws a link between sickness behaviour and 
delirium. Sickness behaviour includes: malaise, increased somnolence, decreased cognitive 
ability, low mood, social withdrawal, decreased motor activity, anorexia, and fever.(15, 16) 
These behavioural and neuro-endocrine changes are exaggerated in delirium due to aberrant 
homeostasis. Immune-inflammation dysregulation is hypothesised to include: an increased 
pro-inflammatory milieu, Hypothalamic pituitary-axis (HPA) derangement, and microglial 
cell dysfunction. 
Sickness behaviour changes are triggered by a predominance of pro-inflammatory cytokines. 
Elevated levels of IL-8, INF γ, CRP, low baseline IGF-1, and IL-1RA levels have been found 
to be predictive of delirium.(16, 17) Anti-inflammatory cytokines act by downregulating 
ischaemic and excitotoxic neural damage, and inhibiting the induction of the inflammatory 
reaction by amyloid β peptide.(16-19)  
Aged patients, or those with neurodegenerative disease, have a more pronounced response to 
systemic inflammation; this observation has been supported by animal models.(15, 20) Part 
of this exaggerated response is thought to be HPA over activity, and impaired negative 
feedback, combined with sustained high levels of cortisol in response to peripheral 




and neuropsychiatric disease. Cortisol is also elevated in patients with neurodegenerative 
disease.  
Microglial cells are the resident CNS macrophages, these cells are primed by chronic 
neurodegenerative disease to increase in number and express more markers of 
phagocytosis.(9) It is hypothesised that microglia are primed in the aged, or those with 
neurodegenerative disease, to amplify the CNS inflammatory response to a peripheral 
insult.(15, 21, 22)  
The pathophysiology of delirium is complex and poorly understood; further study in this area 
could elucidate possible markers of delirium severity and/or markers to help identify patients 
who are at risk of delirium. 
 
Delirium risk factors 
While a single noxious event can precipitate delirium, the aetiology is most often 
multifactorial.(2) The risk factors for delirium can be divided into two categories: 





Table 1: Risk factors for Delirium in Medical patients
†
 






- Intellectual impairment 
Sensory deficits  
- Hearing  
- Vision 
Functional impairment 
Severity of illness 









- Electrolyte abnormalities e.g. Sodium 
- Organ Dysfunction e.g. elevated urea 
and ammonia in kidney and liver 
failure, respectively 




- Stroke: infarct / haemorrhage 
- Infection 
- Trauma  
Iatrogenic 
- Adding > 3 medications  
- Use of anticholinergics, sedation, 
opiates, corticosteroids and NSAIDs 
- Restraints  
- Indwelling catheter 
- Poor pain management 
Constipation and urinary retention 
Environmental changes 
†
(1, 5, 7, 13, 23-27) 
Patients with cognitive dysfunction, especially dementia, are at a higher risk of delirium. 
These patients develop delirium in response to minor stimuli, and tend to have a protracted 
course of delirium with more severe and longstanding cognitive decline.(13) Conversely, 




be at lower risk of delirium: Jones et al. found that each year of completed education was 
associated with lower odds of delirium OR 0.91 (95% CI: 0.87-0.95, p<0.01).(28) However, 
at least one other study found that education offers no protection from delirium.(29) 
Drugs are the most common and reversible cause of delirium, accounting for 12%–39% of all 
cases.(30) A recent systematic review found that when psychoactive medications 
(anticholinergics, benzodiazepines, opioid analgesics, steroids, antidepressants, 
antipsychotics, and antihistamines) were grouped as a variable there was a significantly 
increased risk of delirium in five studies. However, the review was under powered, limited by 
the heterogeneity of the studies, and inconsistent statistical analyses.(31) Drugs with 
anticholinergic activity are well described as causes of delirium,(9, 10) while Benzodiazepine 
use has been found to be an independent risk factor for cognitive impairment with an adjusted 
OR of 3.5 (95% CI: 1.4-8.8).(32) Table 2 presents a summary of groups of medications 





Table 2: Examples of medications that cause delirium
†
 
Group of medication Examples Mechanism 
Antiparkinsonian 
agents 









Antihistamines  Diphenhydramine Anticholinergic activity 





Bronchodilator Theophylline Anticholinergic activity 






Corticosteroids Dexamethasone Anticholinergic activity 
Dopaminergic agents Bromocriptine Excess dopaminergic activity 















Prevalence of delirium  
Current delirium literature generally focuses on studies in developed countries within 
geriatric and intensive care populations. The prevalence of delirium is variable, with rates of 
40% in nursing homes and up to 80% in ICU settings.(7, 8) A recent systematic review by 
Siddiqi et al.(8) looked at 21 studies from 1982 to 2005 in general medical wards. This 
review found that delirium was prevalent in 10-31% of medical inpatients. All but one of the 
studies was based in developed/high income countries with all patients older than 65 years of 
age. The screening, diagnostic methodology, and methods of describing delirium were highly 
variable between the studies.  
 
Impact of Delirium 
This common disorder has many short and long term complications. In the short term, 
delirium results in increased length of hospital stay, greater use of psychical restraints, 
continuous sedation, and has higher rates of complications. These patients have increased 
mortality,(2) with studies showing mortality rates at discharge of 14.5 to 37%.(8, 23) Long 
term complications include prolonged delirium (up to 12 months), post discharge 
institutionalisation, as well as functional and cognitive decline. Patients diagnosed with 
delirium have higher rates of future dementia and a 1.5-fold increased risk of death in the 
year following hospitalization.(1, 2, 7, 8, 26) The mortality rate is higher in the following 
cases: undetected delirium, hypoactive delirium, young patients, and patients who are 
restrained.(1, 23) Literature also shows that between 32-67% of delirium cases remain 
unrecognised in general medical wards.(35) Not only does delirium have serious implications 
for patients, health care systems also carry the burden of this disease. In the United States 




delirious patients. The burden on the health care system in developed countries rivals the cost 
of falls and diabetes mellitus.(36)  
Delirium is a common, serious medical condition that is often misdiagnosed in a clinical 
setting, and is associated with poor short and long term outcomes, higher risk of mortality, 
and increased health care costs.(8) 
 
Delirium in developing countries  
There has been little research done in delirium in medical inpatients in Sub-Saharan Africa 
(SSA), with the majority of studies being conducted in psychiatry and intensive care 
settings.(37-40). Paddick et al.(37) recently published a systematic review of 46 papers from 
16 SSA countries with the majority of the papers coming from Nigeria (n=15), South Africa 
(n=6), and Senegal (n=5). The review contains several limitations, namely that delirium was 
the main focus of only one cross-sectional study; there was no standard criteria used for 
diagnosis of delirium, and most of the patients investigated were not tested for HIV. Several 
studies on the delirium rates on Sub-Saharan African cohorts have shown that there is a high 
variability in the rates of delirium between population groups. Notably, the rates of delirium 
in SSA are 3.7-29.9% in psychiatric patients,(37, 39, 40) 15 % in palliative care patients,(41) 
and 51% in an intensive care setting.(38) A recent study looking at delirium in older acute 
medical admissions (>60years of age) in Tanzania found a delirium prevalence of 19.2% 
(95%CI: 15.7 – 22.7).(42) Despite these studies, and an extensive literature review, there is 
no data on the prevalence, risk factors for, and outcomes of delirium in the HIV positive 
general medical in-patients in SSA. 
The most common risk factors for delirium are dementia, polypharmacy/medication side 




most common risk factors for delirium were HIV (3.7–30.1%), patients admitted for 
palliative care (15%), Typhoid (14%), liver disease (12.9%), heart disease (12.5%), and 
Malaria (10%).(37) While a recent study on older medical in patients in Tanzania found that 
significant risk factors for delirium in their population were similar to risk factors in high 
income countries. The most significant risk factors were: increasing age, male gender, pre-
existing dementia, physical dependency, degree of illness severity, and current alcohol 
use.(42) 
The outcomes of delirium are well described in high-income countries, but the outcomes of 
delirium in low-income countries are not readily available. In India, a research group 
investigating delirium in general medical wards, found that delirious patients had an inpatient 
mortality rate of 12.4% (41/331) with a mortality rate at 6 months of 28%, in two studies 
respectively.(44) Another Ugandan multicentre study of delirium in ICU patients found an 
inpatient mortality rate of 55.45%; however, the length of ICU stay was not significantly 
different to patients without delirium.(38) There are no studies about the outcomes of general 
medical patients with delirium in SAA. 
 
HIV in South Africa 
South Africa has one of the highest prevalence rates of HIV infection, with almost 20% of the 
global HIV positive population living in the country.(45) The number of HIV infected 
individuals has risen from 5.48 million in 2011 to 6.19 million in 2015, and the antenatal HIV 
seroprevalence in Khayelitsha in 2013 was 34.4%.(46, 47) A recent study in a Cape Town 
hospital showed that HIV still accounts for more than two thirds of total general medical 
admissions. The most common presenting diagnoses being AIDS defining illnesses 




(MODs)).(47) South Africa launched the National ART roll out programme in 2004, and by 
2013 there were an estimated 2.3 million people on ART.(45) Between 2003 and 2011, after 
the roll out of ART, life expectancy in rural Kwa-Zulu Natal increased by 20% (from 49.2 to 
60.5 years).(48) Due to the increased life expectancy and the fact that all HIV positive people 
now have access to ART regardless of CD4 count (based on the new national and WHO 
treatment guidelines),(45) there will soon be an aging HIV positive population that will be at 
higher risk for delirium. 
Previously, South Africa’s primary focus was on HIV incidence and prevalence in women of 
childbearing age, as this was assumed to be a high risk group.(49) However, a recent model 
showed that HIV prevalence in adults >50 years of age in SSA will triple by 2040 (from 3.1-
9.1 million).(50) South Africa has the highest proportion of older people in its population 
than any other SSA country.(49) A 2012 survey by the South African Human Sciences 
Research Council found the prevalence of HIV in amongst adults aged 50-54 is 13%, while 
the average prevalence for all adults >50 years is 7.6%.(51) These prevalence rates are not 
significantly different to the 15-25 year age group (p=0.511), although the older age group 
has a higher percentage of males and residents of informal rural/urban areas (51) A survey 
conducted in rural KwaZulu-Natal found that being >65 years of age was an independent risk 
factor for a positive HIV status (adjusted OR 0.2, p<0.001) and the incidence rate of HIV in 
adults >50 years was 0.5 (95% CI 0.3 - 1.0) per 100 person-years overall.(52). There is a 
higher mortality rate in the older HIV population as they are more prone to TB, non-
communicable diseases, and have a slower response to ARVs.(53, 54) Despite the high 
prevalence and incidence of HIV in this age group, there is a bias towards not screening for 




HIV in the elderly leads to lower CD4 counts at presentation and rapid progression of 
disease.(55) 
In addition to the massive burden of HIV infection there has been an escalation of non-
communicable diseases in South Africa. In 2012, The World Health Organisation estimated 
that non-communicable diseases (cardiovascular disease, cancers, chronic respiratory 
diseases, and diabetes) accounted for 48% of deaths in South Africa, with a 27% probability 
of dying from one the 4 main non-communicable diseases in the population aged 30 – 70 
years.(56) Up to 30% of South African patients >50 years have two or more chronic 
conditions.(57) Although older patients are more likely to be adherent to medication, 
adherence is decreased in patients taking multiple medications.  
In the years to come, South Africa will have an aging HIV positive population with a high 
burden of non-communicable diseases. This group will also be at risk for traditionally 
geriatric problems such as frailty, falls, dementia, and delirium.(58) Previous studies in SSA 
have shown that HIV and infections are risk factors for delirium, therefore it would be 
inferred that this aging HIV positive patients would be at higher risk of delirium.(37)  
Literature Review 
 
Objectives of the literature Review 
We aimed to identify the published prevalence, the risk factors for and the outcomes of 
delirium in HIV positive patients with a focus on hospitalised patients in countries with a 







Literature Search Strategy 
An overview of contemporary literature (up to 28 February 2018) was undertaken through a 
comprehensive search strategy on academic literature databases to which the University of 
Cape Town subscribes (Pubmed, EBSCO host (CINAHL, Academic Search Premier, 
African-wide Information), Cochrane and Medline). More information regarding the search 
strategy and prioritisation can be found in the flow diagram below: 
Figure 1: Research flow diagram 
 
After Search: 84 papers  
(excluding 14 duplicates) 
MeSH terms (("Acquired Immunodeficiency 
Syndrome"[Mesh]) OR "HIV"[Mesh]) AND "Delirium"[Mesh] 
("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND 
("delirium"[MeSH Terms] OR "delirium"[All Fields]) 
 
Excluded: 63 papers  
- Incorrect topic 
- Focus on children and adolescents 
- Focus on psychiatric illness in HIV in general 
- Not in medical patients 
Reviewed: 21 papers 
- 3 papers in Spanish, Polish, German 
- 12 papers were too broad  (entirity of psychiatric disease in HIV) 
or only dealt with theory 
 
 






Delirium in HIV 
 
Prevalence 
There are very few studies that specifically review delirium in HIV positive patients but the 
prevalence rates are 12-57%, and almost all of these studies are in the pre-ART era.(59-64) 
One study based in Paris found that delirium was the most common neurological 
complication (45%) of HIV positive patients admitted to ICU.(65) A study in Texas looking 
at medical inpatients with HIV referred to psychiatric liaison services found that 57% of the 
referred patients had delirium; of these patients 55% had delirium, 36% had delirium and 
dementia, and 9% had delirium an addition to another organic mental disorder (OMD).(64) A 
retrospective chart review in a Washington specialist HIV nursing facility, found that 
delirium was poorly diagnosed and reported, and that this could account for the variable rates 
of reported delirium in HIV positive patients.(62) Of the 137 charts reviewed only 1 patient 
was recorded as having delirium, whereas the chart review found 64 patients (46%) had 
delirium based on a retrospective CAM. Three studies by Uldall et al.(59-61) in 1994 and 
1996 assessed the outcomes for HIV positive delirious patients in an assisted living centre 
and an American teaching hospital respectively. These studies had small sample sizes but two 
used formal testing with the CAM to assess for delirium. Delirium was present in 12% - 46% 
of patients in these three studies.(59-61) . However, all these studies took place before the 
implementation of combined ART therapy and prophylaxis for opportunistic infections (OIs) 
which may mitigate the mortality in an environment with broad ARV coverage and OI 
prophylaxis.(66, 67) There is little available data with regards to prevalence, risk factors for, 







Very little is known concerning specific risk factors for delirium in the HIV positive 
population. One of the psychiatric liaison studies found that a cause could be found for only 
68% of HIV positive patients with delirium. The most common causes were CNS infections 
(toxoplasmosis, cryptococcal meningitis, and herpes encephalitis), lymphoma, sepsis, 
metabolic encephalopathy, and patients who had both sepsis and metabolic 
encephalopathy.(64) Lalonde et al. similarly found the most common predictors of delirium 
in HIV positive cohort were: medication side effects (48%), fever (38%), and infection 
(20%).(62) This was again similar to another study that found associated medical conditions 
included: medication changes (44%), fever (38%), and infection (26%). This study also found 
that the presence of HIV related illness did not significantly contribute to delirium.(59) Uldall 
et al. found no specific risk factors for delirium in HIV positive patients apart from being 
prescribed ≥3 CNS active medications and that benzodiazepine and narcotic use were 
significantly associated with delirium; this is in keeping with a prospective cohort study by 
Inouye et al., where polypharmacy (the use of, or addition of, greater than three medications) 
was associated with an increase in incident delirium [RR 2.9 (95% CI, 1.6 to 5.4)].(43, 59, 
60, 68) Uldall et al. also found that a low CD4 count was not predictive of delirium.(60)  
HIV neurocognitive impairment (NCI) is a subcortical dementia characterised by behavioural 
changes, memory deficit, and psychomotor slowing.(69-71) Patients with cognitive 
dysfunction, especially dementia, are at a higher risk of delirium.(13) The severity of HIV 
NCI is related to the number of activated CNS macrophages, and the release of macrocyte 
and astrocyte derived products.(69-71) In a recent meta-analysis Habib et al.(72) reviewed 
NCI in HIV-1 infected individuals in Sub-Saharan Africa (SSA). The review looked at 16 




for NCI in HIV positive patients as compared to HIV negative controls. The estimates of NCI 
in adults pre-Anti-Retroviral Therapy (ART) was 42.4 % (95%CI: 32.2–52.6 %) while the 
estimate for adults on ART for greater than six months was 30.4 % (95 % CI: 13.2–47.6 
%).(72) Comparatively, NCI rates in the pre-ART era in the USA were 15-20%.(73) This 
meta-analysis attributed the higher incidence of HIV NCI in its population to the fact that 
patients in SSA have lower performance scores, and typically present later with profound 
immunosuppression. These patients also have a higher incidence of opportunistic infections 
and anaemia.(72) Risk factors for HIV NCI include advancing age, high HIV viral load (VL) 
early in infection, low CD4 counts, low body mass index, anaemia, female gender, and 
injection drug use.(69) As neurocognitive impairment is a well described risk factor for 
delirium, it is not surprising that studies have shown high, but variable, prevalence rates of 
delirium in the HIV positive population of between 3.7-57%.(37, 62-64) Furthermore, 8-22% 
of cases present with concurrent NCI.(60, 61, 72, 74)  
 
Prognosis 
In two studies, Uldall et al. found that HIV positive patients with delirium had significantly 
longer hospital stays and were more likely to need specialised care if discharged alive. These 
patients had higher rates of mortality than those without delirium, and that delirium was an 
independent marker of inpatient mortality in HIV positive patients with a mortality rate of 
63% and 97% respectively.(59, 60) Fernandez et al. found that in their selected study group 
50% of HIV positive patients with delirium had only partially reversible delirium while 13% 
progressed to a more chronic OMD (the most common being dementia). However, even the 
HIV positive patients with fully reversible delirium had behavioural and cognitive 





South Africa has a high prevalence of HIV and non-communicable diseases, in a region with 
high rates of delirium. This population is therefore at risk of the complications associated 
with delirium, including increased morbidity, increased mortality, and greater costs to the 
health system. It is important to establish an awareness of risk factors in this is population to 
allow early identification and prevention of delirium. An extensive literature review showed 





Aims and Objectives of the Study: 
 
Aim:  
To identify the prevalence, risk factors, and outcomes of delirium in HIV infected individuals 
admitted to South African hospitals. 
 
Objectives: 
1. To identify the prevalence of HIV in patients admitted to medical wards, using a gold 
standard and validated Questionnaire. 
2. To assess potential risk factors for delirium, including demographic data, disease 
status, admission diagnoses, medication and laboratory data. 
3. To assess the short and medium term mortality rates of HIV patients admitted with 
delirium versus those without. 
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Research in context 
 
Evidence before this study 
We searched PubMed and Medline for articles up to 28 February 2018, using the search 
terms: “delirium”, “HIV”, “mortality”, “risk factors”, “Sub-Saharan Africa (SAA)”, and 
“South Africa”. The majority of published delirium research is confined to HIV uninfected, 
geriatric populations in developed countries. In the one systematic review of delirium in SSA 
only one paper focussed on delirium, most of the patients were not tested for HIV, no 
standard criteria was used for delirium diagnosis; and cohorts were restricted to 
paediatric/adolescent, psychiatric, and ICU populations. Published data on delirium in HIV 
infected patients are few, restricted to developed countries or prior to widespread uptake of 
combination antiretroviral therapy (ART).  
 
Added value of this study 
This is the first study of delirium, diagnosed with validated reference testing, in HIV-infected 
acute medical admissions from a setting with good uptake of ART. In contrast to geriatric 
populations from developed settings, this is a young patient cohort from South Africa - a 
developing country with high burdens of HIV, tuberculosis (TB), and non-communicable 
diseases (NCDs). In this setting, delirium was common and an independent risk factor for 
inpatient mortality in HIV positive patients. Amongst HIV-infected admissions, advancing 
age and uraemia were the main delirium risk factors, while the use of ART at admission was 
protective. Traditional markers of advanced immunosuppression (low CD4 cell count and 
unsuppressed HIV viral load) and active TB did not increase risk for delirium.  
 
Implications of all available evidence  
Delirium is common and an important independent predictor of poor outcome in HIV 
infected acute medical admissions. Older HIV-infected patients with renal dysfunction are at 






Abstract (240/250 ) 
 
Background 
Delirium is associated with increased mortality and hospital length of stay. Limited data are 
available from HIV-infected acute hospital admissions in developing countries. We 
conducted a prospective study of delirium amongst acute medical admissions in South Africa 




Three cohorts of adult acute medical admissions to Groote Schuur and Victoria Hospitals, 
Cape Town, South Africa were evaluated for prevalent delirium within 24 hours of 
admission. Reference delirium testing was performed by either consultant physicians or 
neuropsychologists, using the Confusion Assessment Method (CAM).  
 
Findings 
The study included 1182 acute medical admissions; with 318 (26·9%) HIV-infected. 
Median(IQR) age and CD4 count was 35(30-43) years and 132(61-256) cells/mm3 
respectively, with 140/318(44%) using ART on admission. Delirium prevalence was 
17·6%(95% CI 13·7-22·1%) amongst HIV-infected patients and was an independent risk 
factor for inpatient mortality. In multivariable logistic regression, factors associated with 
delirium were age ≥55 years(AOR 6·95[2·03-23·67], p=0·002) and urea ≥15(AOR 4·83[1·7-
13·44], p=0·003), while ART use reduced risk (p=0·014). Low CD4 count, unsuppressed 
viral load, and active TB were not predictors of delirium; nor were other traditional risk 
factors such as non-opportunistic, acute infections or polypharmacy.  
 
Interpretation 
Delirium is common and predicts poor outcome in HIV-infected acute medical admissions in 
endemic settings despite increased ART use. Older HIV-infected patients with renal 







The prevalence of delirium in acute medical in-patients is high, with estimates ranging from 
10-31%.
1
 Short- and long-term complications of delirium include: increased mortality and 
length of hospitalisation; post discharge institutionalisation, and long-term functional and 
cognitive decline.
2
 This is a considerable healthcare burden; in developed countries the cost 
of delirium is equal to that of falls and diabetes mellitus.
3
 A number of risk factors for 
delirium have been identified, including predisposing factors such as dementia and advancing 
age and acute precipitating factors such as drugs, infections, and metabolic abnormalities.
2
 
Protective factors include a higher level of education (a marker of cognitive reserve).
4
 
Unfortunately, this extensive published data on delirium outcomes and risk factors in general 
medical in-patients comes almost exclusively from geriatric populations in developed 
countries, a very different population to acute medical admissions in developing country 
settings with high HIV/TB burden.
5
 Furthermore, the few studies from developing country 
settings like Sub-Saharan Africa (SSA) have either been conducted in medical patients >60 
years or in specialised populations, such as psychiatric and intensive care settings.
6-8
 In 
developed countries studies have been done amongst HIV-infected populations before 
universal access to combination anti-retroviral therapy (ART) in the United States.
9-14
  
HIV targets the CNS with resultant neurocognitive impairment (NCI); a well-described 
predisposing risk factor for delirium. Acute and opportunistic infections (OIs), also known 
risk factors for delirium, occur more commonly with advancing immunosuppression. Thus, it 
is unsurprising that studies have shown high prevalence rates of delirium (3·7-57%) in the 
HIV-infected population. 
6,11-13
 Delirium in HIV is often concomitant with NCI, in 8-22% of 
cases.
15
 Combination ART both prevents and improves NCI and decreases the incidences of 
acute and OIs, thus widespread access may mitigate delirium risk. Therefore, it is unclear 
amongst acute general admissions in HIV endemic settings with universal ART programmes, 
if HIV infection remains an independent risk for delirium.
9
 Furthermore, in developing 
country settings with high burdens of communicable (CD) and non-communicable diseases 
(NCD), like South Africa, clinicians do not know which delirium risk factors to identify 
amongst HIV-infected admissions. Available data is almost exclusively from before universal 
ART access;
9-13,16
 furthermore, data from SSA populations is highly variable, due to a lack of 
standardised delirium testing methods, or incomplete HIV testing.
6
 We aimed to conduct a 
study amongst acute medical admissions with high HIV burden using standardised delirium 







Study design and participants  
This prospective cohort study focused on HIV-infected acute general medical admissions, 
and was a planned analysis within a parent prospective randomised cohort study designed for 
the development and validation of a novel four-question delirium screening tool, however 
this study used the Confusion Assessment Method (CAM) reference testing. A computer 
generated, random selection of daily acute general medical admissions to two hospitals 
(Groote Schuur (GSH) and Victoria (VWH)) in Cape Town, South Africa, were enrolled for 
the parent study during two phases: 22 August 2009 – 10 December 2009 (Development) and 
11 November 2013 – 7 March 2014 (Validation). GSH is a Tertiary Referral hospital with 
~150 acute general medical admission beds; while VWH is a District Level hospital with ~80 
acute general medical beds. All adult medical patients ≥18 years admitted on weekdays were 
eligible; and a random sample of ten patients per day were selected (usual daily patient intake 
15-25 patients), to allow study staff to perform delirium testing within 24 hours of admission. 
Exclusion criteria included: i) Informed consent declined; ii) Age <18 years; iii) Glascow 
Coma Score 12; and iii) Aphasia (Figure 1).  
If a patient was diagnosed with delirium during reference testing their initial consent was not 
considered valid and the HREC granted an initial waiver of the informed consent 
requirement. When the patient’s delirium had resolved, the study was explained again to the 
patient and written informed consent was taken. If this was not possible as part of the initial 
in-patient admission, then the patient and/or next of kin were contacted and arrangements 
were made to complete consent either in person or telephonically. If the patient was 
uncontactable then the HREC granted a waiver to allow the inclusion of patient data. The 




Within 24 hours of admission, a study physician reviewed the patient’s charts and gathered 
information pertaining to the patient’s primary diagnosis, clinical background, admission 
medication, level of education, and demographic information. An independent study 
physician trained in delirium testing (in the development study) or neuropsychologist (in the 
validation study) then assessed the patient for delirium using the CAM performed during a 
20-30 minute interview consisting of formal cognitive testing.
17
 For either testing tool the 
precence of language barriers was noted (see Figure 1)and a ward based translator was used, 
when possible, so that testing was performed in the patients’ first language. 
HIV status, diagnostic, medication and outcome data acquisition and classification 
 
Investigations, including HIV screening and testing, were performed at the discretion of the 
attending physicians, any patients that refused HIV testing during this admission were 
excluded from the study. A positive HIV status was defined as any record of a positive HIV 
test (either rapid or ELISA) at any point prior to or during index admission dating back to 




electronic system). The CD4 count and HIV viral load (VL) most proximal to or during the 
index admission to a maximum of 12 months preceding admission was included.  
The patients’ primary diagnoses and medications were collected by reviewing admission case 
records, pharmacy records and discharge summaries and assigning ICD 10 codes. We 
analysed the association of delirium with the top five most frequent CDs and NCDs; while 
considering known HIV-associated conditions separately. Categories of medications 
commonly linked to delirium were selected based on published literature;
18
 and all 
medications were assigned to groups as per the South African Medical Formulary. 
Antiretrovirals (ARVs), anti-TB medication, and the medication for prophylaxis of OIs 
(Fluconazole and Trimethoprim/sulfamethoxazole) were assessed as possible protective 
factors for delirium in HIV-infected patients. Detailed information on ICD10 and medication 
groupings is provided in the online supplementary data. Outcome mortality data was obtained 
from patient folders, hospital electronic patient management system and the Western Cape 
Provincial death registry which links a unique patient identification number with national 
death certificate records and system wide electronic records.  
 
Statistical Analysis 
Data were analysed in Stata 14·2 (Stata Corp., College Station, TX).  Continuous variables 
were summarized as frequencies and percentages and categorical variables as medians with 
inter-quartile range (IQR). Socio-demographic, clinical characteristics and outcomes were 
assessed for differences between HIV-infected, HIV-uninfected, and HIV unknown patients 
overall; and restricted to those with delirium. Analysis was then restricted to HIV-positive 
patients to compare socio-demographics, clinical characteristics and outcomes between cases 
with and without delirium. Associations between categorical variables were analysed using 
chi-square test and Fisher’s exact, as appropriate.  Wilcoxon rank-sum or Kruskal-Wallis test 
was used for comparison of continuous variables between two and three groups respectively.  
Univariable and multivariable logistic regression was performed to identify risk factors for 
delirium in HIV-infected patients. Variables analysed in univariable analysis were considered 
a priori, and ROC curve analysis was used for age and urea to determine clinically relevant 
cut off values. Variables were retained in the multivariable model if they were significantly 
associated with outcome (p <0·05). Education >7 years and CD4 count were retained in the 
multivariable model regardless of significance due to their clinical relevance. Odds ratios 








A total of 1565 patients were randomised to the parent study (459 and 1106 in the 
development and validation phases respectively) (Figure 1). Of these, 383 were excluded and 
a total of 1182 patients considered as part of this analysis. The prevalence of HIV-infection 
was 26·9%(318/1182); with 44%(140/318) using ART on admission. Table 1 and Table 2 
describes the cohort stratified by HIV status and then restricted to only patients with delirium. 
Overall, the median (IQR) age was 49·5(34-63·2) years, and 53·1% were female. HIV-
infected patients were younger than both HIV-uninfected and unknown [35(30-43) years vs. 
52·7(38-64·7) years and 66(55·5-75·3) years, p=0·0001). The median(IQR) CD4 count was 
132(61-256) cells/mm
3
. Delirium prevalence was 17·6%(56/318) in HIV-infected patients 
(p=0·161). Overall inpatient and 12-month mortality was 6·2%(72/1182) and 
23·8%(281/1182), with no difference by HIV status. There was no loss to follow up in either 
inpatient or 12-month mortality. Amongst HIV positive patients, delirium was an 
independent predictor of inpatient mortality (14·6% vs 5·4%, p=0·036), but though HIV 
infected patients had a higher 12-month mortality the result was not significantly different 
(33·9% vs 22·9%, p=0·083 respectively). 
Table 1 and Table 2 show primary admission diagnoses, key laboratory parameters and the 
five commonest admission medications. NCDs accounted for more hospital admissions than 
CDs (69·7% vs 27·8%, p<0·0001) and two distinct patient groups are evident. HIV-infected 
patients had low rates of NCDs, and a high burden of TB and other CDs, such as 
meningitis/encephalitis. HIV patients used more medication (15·1% on ≥three medications), 
due to the prescription of ARVs and greater use of anti-TB medication and antibiotics. In 
contrast, the older HIV unknown group, were predominantly admitted with NCDs, and 
NSAIDS and cardiac drug prescribing was higher than in HIV positive patients (p<0·0001). 
These differences were present in comparing the overall patient population and when 
restricted to patients with delirium. This shows that HIV infected patients have an unique 
profile relative to HIV-uninfected general medical admisions. 
HIV-infected patients are compared in Table 3 by the presence or absence of delirium. The 
two groups are similar in terms of age, gender and education status. With the exception of 
renal failure, there were no significant differences in CD or NCD primary diagnoses. 
Similarly, although patients with delirium had lower median CD4 cell counts (104[95% CI: 
32-214] vs 150[95% CI: 62-266], p=0·1284), and lower rates of HIV viral suppression 
(27·3% vs 40%, p=0·519), no statistically significant differences were found. However, the 
delirium group had significantly lower Hb (p=0·0194), higher urea (p=0·0047), and 
creatinine (p=0·0197). A higher number of patients without delirium were using ≥ three 
admission medications (45[17·2%] vs 3[5·4%], p=0·023) with a greater number of patients 
on ARVs, antibiotics, and OI prophylaxis (Sulfamethoxazole / Trimethoprim and 
Fluconazole). However, use of TB medication was similar between the two groups (19·6% vs 
19·5%, p=0·976).  
Table 4 shows the univariable and multivariable logistic regression analysis exploring 
protective and risk factors for prevalent delirium in HIV-infected acute medical admissions. 
For every five year increase in age there is a 25% increased risk of delirium (95% CI: 1·1-1·5 
p=0·008), with an AOR of 6·95(2·03-23·67) using an ROC-selected age ≥55 (p=0·002). On 
univariable analysis, both a primary diagnosis of renal failure [OR=6·3 (95%CI: 1·6-24·4, 




≥15mmol/l retained in the multivariable analysis (AOR 4·83[95%CI: 1·7-13·44], p=0·0003). 
Patients using ≥three medications on admission had a decreased risk of delirium 
(OR=0·3[95% CI:0·1-0·9], p=0·035), with the greatest protective effect from the use of ART 
on admission (AOR=0·34[95% CI: 0·14-0·8], p=0·014). Other NCDs and CDs, including 
TB, or markers of advanced immunosuppression and poor HIV control (CD4 cell count and 




Delirium is a well-established predictor of poor outcomes, both short and long-term, and 
attendant healthcare costs are substantial. However, the overwhelming majority of all aspects 
of published delirium data are concentrated either on specialised populations e.g. ICUs or 
geriatric settings with a median age >65 years.
1,6,19
 Available data from developing country 
settings are highly variable, often lacking standardised delirium testing methods or HIV 
testing and treatment data.
6
 Focussed HIV delirium studies also either come from specialised 
care settings (e.g. psychiatry) or have been conducted prior to universal access to ART.
9-14,20
  
Yet, the majority of in-patient care in health systems worldwide is delivered in medical 
wards; in developing HIV-endemic settings mostly in undifferentiated general medical wards 
Our study is the first to study delirium, using a validated testing method, amongst HIV 
infected inpatients, admitted in the context of an acute general medical intake in a developing 
country with dual CD and NCD burdens
5
, and in the setting of improved access to ART. The 
key findings of our study include: i) Delirium occurs in 14.6% of all acute medical hospital 
admissions , and 17.6% of HIV-infected patients (with 44% ART coverage); ii) Delirium was 
an independent risk factor of inpatient mortality amongst HIV-infected admissions; iii) ART 
use at admission was protective against prevalent delirium; and iv) Age ≥ 55 years and urea 
≥15 mmol/l were associated with an increased risk of delirium amongst HIV-infected 
admissions, rather than markers of advanced immunosuppression (low CD4 cell count), poor 
viral control (VL) or active TB. These findings should inform clinical practice for generalists 
and HIV clinicians in developing country settings.  
 
Despite ART coverage of 44% amongst acute HIV-infected medical admissions, the 
prevalence of delirium is high amongst HIV-infected patients. Furthermore, delirium is an 
independent predictor of increased inpatient mortality. Our cohort delirium prevalence of 
17·6% is consistent with both the 4-30% and 12-57% prevalence figures published in a recent 
review on delirium in SSA
6
, and American studies
12-15,21
 in HIV-infected medical inpatients 
respectively. No data are available on HIV-infected medical inpatients in the ART era. 
Studies show that in general medical wards delirium goes undiagnosed in 32-67% of patients 
and that this group of patients has a higher mortality rate.
22
 Lalonde et al found that only one 
of 46 HIV-infected patients was correctly diagnosed with delirium in a specialist HIV 
center.
11
 These figures together should continue to highlight, that even as ART coverage 
continues to improve, delirium surveillance in developing countries is an important health 
priority. In the UK for example, NICE recommends risk factor and indicator assessment for 
all patients admitted to hospital,
23
 and incident delirium is used as a marker of good clinical 
governance.
24
 No rapid delirium screening tools have been validated in a developing country 
setting where patients are younger and consequently have lower co-morbid dementia rates– 





Older HIV-infected patients with acute renal dysfunction are at high risk for inpatient 
delirium while those using ART on admission seem to be protected. The protective effect of 
ART on delirium risk is not surprising, given its known benefit on the neurocognitive 
impairment associated with HIV.
25
 Similarly, we found three known delirium risk factors to 
be important in our HIV-infected patients on univariable analysis: increasing age, anaemia 
and uraemia. These findings are in keeping with data from Tanzanian and Indian general 
medical inpatient cohorts.
7,26
 Anaemia and uraemia are well described risk factors for 
delirium, and anaemia is also a predictor of mortality in HIV-infected patients.
2,27
 However, 
in our cohort many typical risk factors: acute non-oppurtunistic infections, TB, and 
hyponatraemia were not predictors of delirium. We also found that markers of advanced HIV 
(low CD4 count and unsuppressed VL) were not significant risk factors for delirium; in 
keeping with the one previous study that assessed CD4 count.
9
 Interestingly, in our study we 
found that the more admission medications prescribed, the lower the risk of delirium. This is 
most likely attributable to the pill burden of combined ART and requirement for OI antibiotic 
prophylaxis in HIV-infected patients. This finding is clearly in contrast to the frequently 
reported link between polypharmacy and delirium in elderly populations;
2
 however, this 
increased risk was also reported in HIV-infected cohorts that found the use of ≥ three CNS 
active medications and medication side effects were key risk factors for delirium.
9,11
  , 
Medications that significantly contributed to delirium in another study were benzodiazepines 
and narcotics,
21
 this was also not found in our study. Notably, all studies were in the pre-
combination ART era and use was not reported.  
 
This study is the largest study to conduct formalised delirium testing in HIV-infected acute 
medical admissions. Nevertheless, despite this large overall study size, there were only 56 
cases of delirium amongst the HIV-infected group. Thus, we had limited power to detect 
small differences between groups, and regression analysis findings should be interpreted 
cautiously. Our findings will need validation in other developing HIV-endemic country 
settings. Another limitation was the lack of mandatory HIV testing on admission, leading to a 
concern about possible inclusion bias. Fortunately, only ~13% of patients were HIV unknown 
out of a large cohort, and there was very little missing CD4 cell count data. The HIV 
unknown cohort was a group of older patients with more NCDs, less infections, and less TB, 
likely thought by attending clinicians to be low risk for HIV infection. Although, assessing 
prevalent delirium on admission may be difficult due to incomplete available information as 
well as the fluctuating nature of the condition, a further period of observation would only be 
expected to increase this prevalence. 
 
Delirium is common, poorly recognised, and has high morbidity and mortality with 
significant costs for health care systems.
3
 We have shown that even with improved ART 
coverage, delirium is common and an independent predictor of mortality in HIV-infected 
patients in a developing country setting with a dual burden of HIV and TB, as well as a 
growing burden of NCDs. Clinicians need to be aware that aging HIV-infected patients who 
are not on ART and who have renal failure are at risk for delirium. In addition, a low CD4 
count and elevated viral load does not likely increase the risk of delirium. Further delirium 
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CAM: Confusion Assessment Method, CRF: Case Report Form, GSH: Groote Schuur Hospital, HIV: Human Immunodeficiency Virus, VWH: Victoria 
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Figure 1: Consort diagram 
  
Acute general medical admissions to two 
hospitals during two phases of enrolment: 
August to December 2009 (Development) November 2012 to 
March 2013 (Validation) 
 
Patients randomised to study, n= 1565 
Development GSH, n= 459 
Validation GSH, n=609, VWH, n=497 
 
Excluded: n= 383  
1. Informed consent declined: n=45 
2. Repeat admission: n=73 
3. Patients <18 years: n=12 
4. Patients who had GCS <12: n=61 
5. Aphasia: n=62 
6. Not admitted to a general ward 
(i.e. patients admitted to  
the ICU): n=35 
7. Died before testing: n=11 
8. Refused an HIV test: n=25 
9. No CAM testing: n=35 
10. CRF missing: n=17 













*Other: n=7 (Language barrier, deaf, elective admission)  
Patients included in final analysis, n= 1182 
Development GSH, n= 395 












HIV not tested 
(n=160) 
P value 
Age in years, med(IQR) 49·5(34-63·2) 35(30-43) 52·7(38-64·7) 66(55·5-75·3) 0·0001 
Female, n(%) 627(53·1) 197(62) 335(47·6) 95(59·4) <0·0001 
Education ≥7 years, n(%) 830(75·9) 230(79) 488(74·9) 112(74·2) 0·332 
Delirium present, n(%) 172(14·6) 56(17·6) 97(13·8) 19(11·9) 0·161 
Dementia/cognitive deficit, n(%) 52(4·4) 8(2·5) 24(3·4) 20(12·5) <0·0001 
Primary diagnosis: n(%)1, n=1153      
Non-communicable disease (NCD) 
total 
824(69·7) 141(44·3) 544(77·3) 139(86·9) <0·0001 
4  most common NCDs      
- CVS combined 238(20·1) 29(9·1) 149(21·2) 60(37·5) <0·0001 
- Respiratory 94(8) 11(3·5) 72(10·2) 11(6·9) 0·001 
- Cerebrovascular 70(5·9) 4(1·3) 49(7) 17(10·6) <0·0001 
- Renal failure 42(3·6) 9(2·8) 30(4·3) 3(1·9) 0·293 
Communicable disease (CD) total 329(27·8)) 142(44·7) 165(23·44) 22(13·8)) <0·0001 
4 most common CDs      
- TB total 145(12·3) 92(28·9) 51(7·2) 2(1·3) <0·0001 
- Pulmonary TB 75(6·4) 35(11) 39(5·5) 1(0·6) <0·0001 
- TB meningitis 20(1·7) 15(4·7) 5(0·7) 0 <0·0001 
- Disseminated TB 33(2·8) 28(8·8) 5(0·7) 0 <0·0001 
- Pneumonia 88(7·5) 27(8·5) 52(7·4) 9(5·6) 0·528 
- Meningitis / Encephalitis 21(1·8) 11(3·5) 9(1·3) 0 0·040 
- UTI 20(1·7) 0 16(2·3) 4(2·5) 0·005 
Laboratory results,med(IQR)      
- WCC, n=1124 9·2(7·1-11·6) 8(5·7-9·6) 9·5(7·6-12·4) 9·6(8·5-12·4) 0·0001 





- Sodium, n=1102 138(135-141) 135(132-139) 139(135-141) 140(138-143) 0·0001 
- Urea, n=1101 7·1(4·7-9·7) 5·9(4-8·9) 7·2(4·9-9·8) 8·5(6·6-9·8) 0·0001 
Medication      
Absolute number of medication ≥3 90(7·6) 48(15·1) 28(4) 14(8·8) <0·0001 
5 most common admission 
medications, n(%) 2 
     
- NSAIDs 230(19·5) 9(2·8) 138(19·6) 83(51·9) <0·0001 
- Cardiac Medications 169(14·3) 6(1·9) 109(15·5) 54(33·8) <0·0001 
- Steroids 131(11·1) 11(3·5) 101(14·4) 19(11·9) <0·0001 
- TB medication 99(8·4) 62(19·5) 36(5·1) 1(0·6) <0·0001 
- Antibiotics 62(5·3) 49(15·4) 13(1·9) 0 <0·0001 
Mortality, n(%)      
- In-patient 72(6·2) 22(7) 40(5·8) 10(6·3) 0·7540 
- 12 months 281(23·8) 79(24·8) 167(23·7) 35(21·9) 0·7710 
 
 
1 See Appendix 1 for detailed diagnoses 
2 See Appendix 2 for details of medications 
 
CD: communicable disease, CVS: cardiovascular system, Hb: Haemoglobin, HIV: Human Immunodeficiency Virus, IQR: Inter-quartile 
range, NCD: non-communicable disease, NSAIDs: Nonsteroidal anti-inflammatory, TB: Tuberculosis, UTI: urinary tract infection, WCC: 
white cell count 



















Age in years, med(IQR) 53(37-66·5) 34·5(30-45) 57(46-69) 76(61-82) 0·0001 
Female, n(%) 87(50·6) 33(58·9) 43(44·3) 11(57·9) 0·175 
Education ≥7 years, n(%) 82(67·8) 28(73·7) 44(63·8) 10(71·4) 0·565 
Dementia/cognitive deficit, n(%) 17(9·9) 3(5·4) 8(8·3) 6(31·6) 0·009 
Primary diagnosis: n(%)1, n=167      
Non-communicable disease 
(NCD) total 
112(65·1) 23(41·1) 75(77·3) 14(73·7) 0·000 
4  most common NCDs      
- Cerebrovascular 16(9·3) 0(0·0) 14(14·4) 2(10·5) 0·003 
- CVS  16(9·3) 2(3·6) 13(13·4) 1(5·26) 0·105 
- Renal failure 11(6·4) 5(8·9) 6(6·2) 0(0·0) 0·432 
- Encephalopathy  5(2·9) 2(3·4) 3(3·1) 0(0·0) 1·000 
Communicable disease (CD) total 55(32) 28(50·0) 22(22·7) 5(32) 0·002 
 3 most common CDs1      
- TB total 25(14·5) 16(28·6) 9(9·3) 0(0·0) 0·001 
- Pulmonary TB 12(7) 5(8·9) 7(7·2) 0(0·0) 0·562 
- TB meningitis 6(3·5) 4(7·1) 2(2·1) 0(0·0) 0·287 
- Disseminated TB 7(4·1) 7(12·5) 0(0·0) 0(0·0) 0·001 
- Pneumonia 13(7·6) 7(12·5) 4(4·1) 2(10·5) 0·123 
- UTI 7(4·1) 0(0·0) 5(5·2) 2(10·5) 0·067 
Laboratory results, med(IQR)      
- WCC, n=169 9(6·7-12·4) 8·3(5·9-9·7) 9·4(8-13·6) 9·1(5·8-12·5) 0·0154 
- Hb, n=169 10·1(9-12·8) 9·5(8·1-10·3) 11·1(9·5-13·7) 10·6(9·7-13·8) 0·0001 
- Sodium, n=167 138(132-143) 134·5(131-140) 139(135-143) 142(137-150) 0·0003 
- Urea, n=166 8·6(5·5-23·4) 7·2(4·5-16·7) 9·4(6-25·2) 9·8(8·2-26·3) 0·0666 
Medication      
Absolute number of medication ≥3 11(6·4) 3(5·4) 66·2) 2(10·5) 0·739 
5 most common admission 
medications, n(%)  
     
- NSAIDs 29(16·9) 0(0·0) 19(19·6) 10(52·6) 0·000 
- Cardiac 23(13·4) 0(0·0) 18(18·6) 5(26·3) 0·000 
- TB medication 18(10·5) 11(19·6) 7(7·2) 0(0·0) 0·024 
- Mood stabilisers 11(6·4) 3(5·4) 8(8·3) 0(0·0) 0·489 
- Antipsychotics 7(4·1) 0(0·0) 5(5·15) 2(10·2) 0·067 
Mortality, n(%)      
- In-patient 26(15·6) 8(14·6) 14(15·1) 4(21·1) 0·710 
- 12 months 65(37·8) 19(33·9) 37(38·1) 9(47·4) 0·582 
1 All other diagnoses < 3% 
CD: communicable disease, Hb: haemoglobin, IQR: inter quartile range, Med: median, NCD: non-communicable disease, NSAIDs: non 
steroidal anti-inflammatory drugs TB: tuberculosis, UTI: urinary tract infection, WCC: white cell count, 











Age in years, med(IQR) 34(30-43·1) 34·6(29·4-41·7) 0·373 
Female, n(%) 33(58·9) 164(62·6) 0·608 
Education ≥ 7years, n(%) 28(73·7) 202(79·8) 0·385 
Primary diagnosis: n(%)1, n=3372    
Non-communicable total 23(41·2) 118(45·0) 0·588 
4  most common NCDs    
- CVS combined 2(3·6) 27(10·3)7 0·131 
- Respiratory 0 11(4·2) 0·223 
- Renal failure 5(8·9) 4(1·5) 0·010 
- Liver failure 0 5(1·9) 0·591 
Communicable total 28(50) 114(43·5) 0·375 
4  most common CDs    
- TB total 18(32·1) 74(28·2) 0·559 
- Pulmonary TB 5(8·9) 30(11·5) 0·814 
- TB meningitis 4(7·1) 11(4·2) 0·312 
- Disseminated TB 7(12·5) 21(8) 0·299 
- Pneumonia 7(12·5) 20(7·6) 0·287 
- Meningitis / Encephalitis 2(3·6) 9(3·4) 1·000 
- Sepsis 0 3(1·2) 1·000 
HIV specific diagnoses, n(%) 3 10(17·9) 44(16·8) 0·847 
3  most common4    
- CCM 3(5·4) 8(3·1) 0·417 
- PJP 0 8(3·1) 0·359 
- HAND 4(7·14) 6(2·29) 0·079 
Laboratory results, med(IQR)    
- CD4, n=302 104(32-214) 150(62-266) 0·1284 
- Viral suppression5, n=86 3(27·3) 30(40) 0·519 
- WCC, n=309 8·3(5·9-9·7) 8(5·7-9·5) 0·6299 
- Hb, n=308 9·5(8·1-10·3) 9·8(8·7-12·1) 0·0194 
- Sodium, n=297 134·5(131-140) 135(132-139) 0·3279 
- Urea, n=297 7·2(4·5-16·7) 5·7(3·9-8·5) 0·0047 
- Creatinine, n=306 83(65-208) 76(58-94) 0·0197 
- CRP, n=185 76·2(28·9-135·2) 45·7(20-107·1) 0·3522 
Admission Medication, n(%) 6    
- Absolute number of medication ≥3 3(5·4) 45(17·2) 0·023 
- ARVs 14(25) 126(48·1) 0·002 
- Sulfamethoxazole / Trimethoprim 3(5·4) 38(14·5) 0·078 
- Fluconazole 0 7(2·7) 0·611 
- TB medication 11(19·6) 51(19·5) 0·976 
- Antibiotics 4(7·1) 45(17·2) 0·067 
Mortality, n(%)    
- In-patient 8(14·6) 14(5·4) 0·036 
- 12 months 19(33·9) 60(22·9) 0·083 
 
1 See Appendix 1 for detailed diagnoses  
3 See Appendix 3 for details of HIV specific diagnoses 
219 patients had dual primary diagnoses i·e· CCM and Pulmonary TB 
4All other diagnoses <3% 
5Lower than detectable limit or <20 RNA copies /million 
6 See Appendix 2 for details of medication  
7The diagnoses in this group were: venous thromboembolic disease (29·6%) and cardiac failure (29·6%), cardiomyopathy (11·1%) and 
pericarditis (11·3%)·  
 
ARVs: Anti-Retroviral, CCM: Cryptococcal meningitis, CD: communicable disease, CRP: C-reactive protein, CVS: cardiovascular system, 
Hb: haemoglobin, HIV: Human Immunodeficiency Virus, IQR: inter-quartile range, NCD: non-communicable disease, NSAIDs: 
nonsteroidal anti-inflammatory drugs, PJP: Pneumocystis jerovici pneumonia, TB: tuberculosis, UTI: urinary tract infection, WCC: white 
cell count 
 








(OR, 95% CI) 
P value Multivariable 
 (AOR, 95% CI) 
P value 
Age( five year increase) 1·12 (0·99-1·3) 0·065   
Age ≥55 years 4·1 (1·6-11·1) <0·0001 6·95(2·03-23·67) 0·002 
Education (≥7 years) 0·71 (0·3-1·6) 0·386 0·76(0·3-1·95) 0·583 
Laboratory values     
- CD4 continuous1 0·99(0·99-1) 0·241 0·84(0·79-1·05) 0·22 
- Hb 0·9(0·8-0·98) 0·025 0·91(0·79-1·05) 0·22 
- Urea1 1(1-1·1) 0·008   
- Urea ≥15 5·0 (2·3-10·7) <0·0001 4·83(1·7-13·44) 0·003 
Medication     
- ARVs 0·4(0·2-0·7) 0·002 0·34(0·14-0·8) 0·014 
1Logarithmic analysis in Multivariable models  
 
AOR: Adjusted odds ratio, ARVs: anti-retroviral drugs, CCM: Cryptococcal meningitis, CD: communicable disease, Hb: Haemoglobin, 
HIV: Human Immunodeficiency Virus, IQR: inter-quartile range, NCD: non-communicable disease, TB: tuberculosis, WCC: white cell 
count, 








Primary diagnosis, n=1207 n(%) 
Noncommunicable Disease 824(69·7) 
CVS combined 238(20·1) 
- Hypertension (HPT)  
- Ischaemic heart disease (IHD)  
- Congestive cardiac failure (CCF)  
- Valvular and nonvalvular heart disease (other than HPT, 
IHD and CCF) 
 
- Venous thromboembolic disease (VTE):Deep vein 
thrombosis) DVT and Pulmonary Embolism (PE) 
 
Respiratory combined 94(8) 
- Chronic Obstructive Pulmonary disease (COPD)  
- Asthma  
- Respiratory disease other than COPD and Asthma e·g· 
Interstitial lung disease 
 
Cerebrovascular 70(5·9) 
- Ischaemic and haemorrhagic stroke  
- Intracranial bleed  
Renal failure: Acute and chronic 42(3·6) 
Fluid / electrolyte imbalances 16(1·4) 
Delirium/encephalopathy 14(1·2) 
Liver failure 12(1) 
Other 338(28·6) 
- Cancer  
- Non- cerebrovascular disease neurological disease e·g· 
CIPD, peripheral neuropathy 
 
- Endocrine disorders e·g· Hypo/hyperthyroidism, 
Diabetes Mellitus (DM) 
 
- Renal disease other than AKI and CKD e·g·Nephritic 
syndrome 
 
- Gastrointestinal disease  
- Rheumatological disease  
- Psychiatric disease  
- Haematology  
- Other e·g· pregnancy, trauma, iatrogenic  
Communicable disease 329(27·8) 
- TB total 145(12·3) 
- Pulmonary TB 75(6·4) 
- TB meningitis 20(1·7) 
- Disseminated TB 33(2·8) 
- Pneumonia 88(7·5) 
- Meningitis / Encephalitis 21(1·8) 
- UTI 20(1·7) 
- Gastroenteritis 19(1·6) 
- Sepsis 12(1) 
- Other e·g· Disseminated gonococcosus 29(2·5) 
 











 Hyoscine butylbromide 






Antispasmodics  Metoclopramide 























Mood stabilisers Lithium 















































 Penicillin G 
 Penicillin VK 
 Piperacillin/tazobactam 
 Streptomycin 
 Sulfamethoxazole / trimethoprim 
 Vancomycin 







 Lamivudine / zidovudine 




 Tenofovir / Emtricitabine / Efavirenz 
 Zidovudine 








 Rifampicin / Pyrazinamide / Isoniazid / Ethambutol 
 Terizidone 
CCM prophylaxis Sulfamethoxazole / trimethoprim 
PJP Prophylaxis Fluconazole 
 





HIV Specific Diagnoses, n=54 Frequency, n(%) 
Cryptococcal Meningitis 11 
Pneumocystis jerovici pneumonia 8 
Kaposi’s sarcoma 3 
Progressive multifocal leukoencephalopathy (PML) 1 
Toxoplasmosis 1 




Dementia in HIV 10 
Immune reconstitution inflammatory syndrome (IRIS) 2 
HIV not specified 10 
 






(OR, 95% CI) 
P value 
Age( five year increase) 1·12 (0·99-1·3) 0·065 
Age ≥55 years 4·1 (1·6-11·1) <0·0001 
Education (≥7 years) 0·71 (0·3-1·6) 0·386 
HIV specific diagnosis   
- CCM 1·8 (0·5-7) 0·398 
Primary diagnosis   
Non-communicable (NCD)   
- Renal failure 6·3(1·6-24·4) 0·007 
Communicable (CD)   
Infection and TB composite 1·30(0·73-2·31) 0·376 
TB composite 1·2(0·6-2·2) 0·56 
- Disseminated TB 1·6(0·7-4) 0·286 
- TB meningitis 1·8(0·5-5·7) 0·351 
Infection composite excluding TB 1·2(0·6-2·6) 0·599 
- Pneumonia 1·7(0·7-4·3) 0·24 
- Meningitis 1·0(025) 0·96 
Laboratory values   
- Viral Suppression1  0·6(0·1-2·3) 0·422 
- CD4 continuous2 0·99(0·99-1) 0·241 
- WCC 1(1-1) 0·931 
- Hb 0·9(0·8-0·98) 0·025 
- Sodium 0·98(0·9-1·1) 0·439 
- Urea2 1(1-1·1) 0·008 
- Urea  ≥15 5·0 (2·3-10·7) <0·0001 
- Creatinine 1(1-1) 0·002 
Medications   
- Total Medication 0·6(0·5-0·9) 0·004 
- Absolute number of medications ≥3 0·3(0·1-0·9) 0·035 
- ARVs 0·4(0·2-0·7) 0·002 
- TB medication 1(0·5-2·1) 0·976 
- Sulfamethoxazole / Trimethoprim 0·3(0·1-1·1) 0·076 
- Antibiotics 0·4(0·1-1·1) 0·068 
1 
Lower than detectable limit or <20 RNA copies /million 
 









Appendix 1: RECALL STUDY CONSENT 
 
Acute cognitive dysfunction: short- and long-term 
outcomes following hospitalisation for general medical 
illness in Cape Town, South Africa 
RECALL-CT Study Patient Informed Consent Form 
 
This research study is about patients who present to hospital with an acute general medical illness and 
possible confusion. You are invited to participate because you fall into this category. 
 
The purpose of the study is to find out whether  
1) a simple 4-question test can diagnose acute confusion in people soon after being admitted to 
hospital, compared with longer tests that take 20-30 minutes to complete and must be performed by a 
very experienced doctor; and  
2) Whether a more intensive medical follow-up period after discharge from hospital will improve 
health outcomes in the 12 months after leaving the hospital. Currently it is unknown whether the 
short-form diagnostic test is effective and whether more intensive follow-up will be better than 
current practice.  
 
This study has been approved by the UCT FHS Human Research Ethics Committee. 
 
Inclusion criteria  
Patient admitted to a general medical ward (including within hospital transfer e.g. ICU discharge) 
>18 years and willing and able to give informed consent 
 
Exclusion criteria 
Patient admitted directly to the intensive care unit 




Aphasic patients unable to speak and undergo cognitive testing 
 
Scientific Importance and Need of the Study 
In medical wards, because of high demand, doctors have limited time with each individual patient. 
This makes the need for quick diagnosis and treatment of acutely ill patients with possible confusion 
important. Confusion associated with acute medical illness is a serious problem that should receive 
early attention. Tools are needed to diagnose and manage patients with confusion. This study will 
investigate whether a particular diagnostic tool is effective and quick and whether an affordable and 
sustainable package of medical intervention after hospital discharge can improve patient outcomes.   
 
If you agree to join this study project, you will be requested to do the following: 
A doctor will complete a special “4-RACY” delirium questionnaire with you, by asking you four easy 
questions 
Within 24 hours, a different doctor will complete another standardised delirium questionnaire, which 
is a little longer (20-30 minutes), to see how the results compare with those from the 1
st
 questionnaire 
After discharge from hospital, you may be contacted telephonically over the next 12-months to 
enquire about your progress and to remind you about your medical follow-up 





You may not benefit directly from participation in the study but we would be grateful for your 
assistance to help develop a better diagnostic tool and process. 
 
Risks and discomfort 
The risk of harm flowing from being involved in this study is minimal.  
Any clinical complications arising from your participation in this study will be managed as required 
and covered by the UCT no fault insurance policy.  
 
Incentive and payment 





Refusal to participate or withdrawal from the study 
The decision to participate is voluntary; you are not forced to participate. You may choose not to 
participate; you may also decide to withdraw at any time without any penalty. You do not have to 
explain why you do not wish to participate.  
If, after testing the study team feels that you are confused and therefore unable to provide us with 
informed consent, we will ask permission from a person eligible to give us proxy consent on your 
behalf. We will then endeavour to consent you when your illness resolves either onsite or 
telephonically, once you have been discharged. 
 
Confidentiality 
All information that you provide will be considered confidential and will not be disclosed to the 
extent permitted by law. No mention of your name or any other identifying information will emerge 
on the samples that are drawn or in any publication in connection with this study. Your personal 
information will NOT be stored with the samples. It is important to note that local hospital personnel 
who examine your samples could become aware of your name. As a result, the investigators cannot 
promise total confidentiality, but efforts will be made to maintain confidentiality. No persons other 
than the research staff and the health workers overseeing your care will have right of entry to any 
information that identifies you individually. Only the local investigator will have the key to connect 
the samples and the information attached to your name.  
 
Treatment 
We will inform the doctors treating you about the results of our testing for confusion. However, the 
study team will not make treatment decisions. Your attending medical team will make your medical 
care and treatment decisions.  
 
We encourage you to ask any questions that you may have and during the study you may contact 
either the Research Ethics Committee (021 406 6492) or the principal investigator(s) (021 404-9111) 








I have read the foregoing information/The foregoing information has been read to me. I have had the 
chance to ask questions about it and any questions that I have asked have been answered to my 
satisfaction. 
I consent voluntarily to take part in this study and I understand that I can withdraw at any time from 










Signature _______________________________ Date ___________________ 
 
 
Or person providing proxy consent: 
 
 


















Signature _______________________________ Date ___________________ 
 
 
If initial reference testing diagnosed delirium, and no repeat consent possible: 
 
Patient gives telephonic consent to remain in the study (circle):    Yes     No     Uncontactable 
 














Appendix 2:  RECALL STUDY CRF 1  
 










Intern MO Registrar 
 
 
 1.  Basic Patient Information 
USE STICKER if 
available) 
First Name: First Name 
 
Initials Middle Name 
Surname: Surname 
Folder Number: N N N N N N N N N N 
DOB: D D M M Y Y Y Y 
 
 
 2.  Exclusion Criteria ( Do not perform RACY if any answer is YES in Q3) Y N 
Has this patient electively been admitted? (i.e. Not via casualty, ICU or secondary hospital)   
Is this patient Aphasic?   
Is the patient’s Glasgow Coma Scale ≤ 12/15   
Is the patient already discharged/transferred from/out of the acute general medical service?   
 
 
 3.  RACY Delirium Screening Tool  
Question (Ask questions as they are on Sheet) Score 
R 
 
Ask Person to Recognise 2 people – “Do you know who I am?” Who is this person?(Point to  Nurse) 



























 4.  Communication Barriers Present At Time Of Testing (Tick all that Apply) 
Deafness  Dysphonia  Language Barrier  
Visual Impairment  Dysarthria   
 





 5.  Chronic Associated Conditions (Diagnosed prior to admission) 
 
Hypertension? Y N Year Diagnosed?     Target Organ Damage? Y N 
 









Y N Year Diagnosed?     Stage Mild Mod Severe V Severe 
 
Previous TB? Y N Count N N Year last diagnosed? Y Y Y Y 







 line MDR XDR 
 
Cancer? Y N Type? Organ System(s) Stage, If known? Stage 
 
Renal Disease? Y N eGFR  Creatinine   
 
Neuro Disease? Y N Year Diagnosed?     
 





HIV? Neg Pos Refused Not Tested 
Year 
Diagnosed 
Y Y Y Y Stage? 1 2 3 4 





Y N Year Started? Y Y Y Y 
 
 6.  Chronic Medication List (Pre Admission) 
 Name of Drug Dosage Frequency  Name of Drug Dosage Frequency 
1    2    




5    6    
7    8    
9    10    
11    12    
 
 7.  Discharge Palliative Care Assessment 
Would you be surprised if the patient were to die in the next year? Yes No 
Does the patient fulfil any of the following criteria? 
Condition Criteria TICK 
Congestive Cardiac Failure 
 Symptoms despite maximal medical therapy 
 Disabling Shortness of breath at rest (NYHA Class IV) 
 ≥ 5 Admissions in past 6 months 
 Other associated organ involvement 
 
COPD 
 Disabling Shortness of breath at rest (NYHA Class IV) 
 ≥ 5 Admissions in past 6 months 
 
Renal Failure 
 End stage renal disease (GFR <15ml/min) 
 Not suitable / Declined for dialysis 
 
Neurological Disease/Stroke 
 Severely disabling 
 Progressive functional decline 
 Severe dysphagia 
 Recurrent fever and sepsis 
 
Frailty / Dementia 
 Significant functional impairment 
 Unable to do ADLs 
 Incontinence 
 Recurrent infections 
 
Cancer 
 Stage IV malignancy (Metastatic) 
 Not for (further) definitive treatment 
 Spends >50% of time in bed / bedridden 
 
AIDS 
 Stage 3 or 4 disease with dementia 
 Severe cachexia 
 Neoplasm, Failure of HAART 
 
Other  E.g.: Post cardiopulmonary arrest with CNS damage  
 
Appendix 3: RECALL STUDY CRF 2 





 1.1  Consent (Please Tick) 
Yes No Informed consent for Study Participation done? (Please attach Informed Consent Sheet) 




 1.2  Patient Information 
Patient Information 
(Please attach sticker if 
available, otherwise complete) 
First Name: First Name 
Middle Name: Middle Name 
Surname: Surname 
Folder Number: N N N N N N N N N N 
Date of birth: D D M M Y Y Y Y 
Contact Details 
Address: 
House Number, Street Name 
Suburb Postal Code 
Tel (H) N N N N N N N N N N Cell: N N N N N N N N N N 
 1.3  Alternate Contact Details (Provide other contact details where patient may be contacted) 
Alternate Contact Details 
1 
Address: 
House Number, Street Name 
Suburb Postal Code 
Tel (H) N N N N N N N N N N Cell: N N N N N N N N N N 
Alternate Contact Details 
2 
Address: 
House Number, Street Name 
Suburb Postal Code 
Tel (H) N N N N N N N N N N Cell: N N N N N N N N N N 
Alternate Contact Details 
3 
Address: 
House Number, Street Name 
Suburb Postal Code 






2. Barthel Index (Pre-Admission Functioning) 
ACTIVITY SCORE 
Feeding 
 0 = unable 
 5 = needs help cutting, spreading butter, etc., or requires modified diet 
 10 = independent 
0 5 10  
Bathing 
 0 = dependent 
 5 = independent (or in shower) 
0 5   
Grooming 
 0 = needs to help with personal care 
 5 = independent face/hair/teeth/shaving (implements provided) 
0 5   
Dressing 
 0 = dependent 
 5 = needs help but can do about half unaided 
 10 = independent (including buttons, zips, laces, etc.) 
0 5 10  
Bowels 
 0 = incontinent (or needs to be given enemas) 
 5 = occasional accident 
 10 = continent 
0 5 10  
Bladder 
 0 = incontinent, or catheterized and unable to manage alone 
 5 = occasional accident 
 10 = continent 
0 5 10  
Toilet Use 
 0 = dependent 
 5 = needs some help, but can do something alone 
 10 = independent (on and off, dressing, wiping) 
0 5 10  
Transfers (bed to chair and back) 
 0 = unable, no sitting balance 
 5 = major help (one or two people, physical), can sit 
 10 = minor help (verbal or physical) 
 15 = independent 
0 5 10 15 
Mobility (on level surfaces) 
 0 = immobile or < 50 yards 
 5 = wheelchair independent, including corners, > 50 yards 
 10 = walks with help of one person (verbal or physical) > 50 yards 
 15 = independent (but may use any aid; for example, stick) > 50 yards 





 0 = unable 
 5 = needs help (verbal, physical, carrying aid) 
 10 = independent 
0 5 10  






 3.  Reference Testing 
 
 3.1 Exclusion Criteria ( Don’t do any further testing if any answer is YES) Y N 
 Has this patient refused consent to be part of the Recall CT study?   
 Has this patient electively been admitted? (i.e. Not via casualty, ICU or secondary hospital)   
 Is this patient Aphasic?   
 Is the patient’s Glasgow Coma Scale ≤ 12/15   
Is the patient already discharged / transferred from /out of the acute general medical service?   
 
 3.2  Known Risk Factors for Delirium (Please tick all that apply) 
 
Condition Y N 
Does the patient’s history suggest any pre-existing cognitive impairment, including dementia?   
Is the patient’s Age ≥ 70?   
Has the patient currently been admitted with a severe/terminal medical illness?   
Does the patient’s immediate history note any history of Depression?   
Does the patient suffer from any significant visual impairment?   
Does the Patient currently have an indwelling catheter?   
 
3.3 Communication Barriers Present At Time Of Testing (Tick all that Apply) 
Deafness  Dysphonia  Language Barrier  





Translator used during testing Y N  
 
 3.4  Patient Education 




Has patient had any schooling? Y N  
Completed Grade? 0 1 2 3 4 5 6 7 8 9 10 11 12 College/University? Y N 
 
 3.5  DSM IV Criteria for Delirium (complete at end with overall assessment) 
Y N 
 Disturbance of consciousness 
  (i.e., reduced clarity of awareness of the environment) with reduced ability to focus, sustain or 
shift attention. 
Y N 
 A change in cognition or the development of a perceptual disturbance that is not better  
 accounted for by a pre-existing, established or evolving dementia 
Y N 
 The disturbance developed over a short period of time (usually hours to days) and tends to  
 fluctuate during the course of the day 
Y N 
 There is evidence from the history, physical examination or laboratory findings that the 





3.6 Mini Mental State Examination (MMSE) 
Instructions: Ask the questions in the order listed. Score 1 point for each correct response within each question or 








5   “What is the Year? Season? Date? Day of the Week? Month?” 
5   “Where are we now: Country? Province? Town/City? Hospital? Floor? 
3   
Examiner names three unrelated objects clearly and slowly (e.g. Ball, Flag, and Table).  
The patient is asked to repeat all three objects.  Give one point for each.  The Examiner 
repeats them until the patient learns all of them, if possible. 
Number of Trials : ______________ 
 
5   
“I would like you to count backward from 100 by sevens.” 
(93, 86, 79, 72, 65) 
Alternative: “Spell WORLD Backwards.” (D-L-R-O-W) 
One point for each correct answer. 
3   
“Earlier I told you the names of three things. Can you tell me what those were?” 
One point for each correct answer. 
2   
Show the patient two simple objects (e.g. Wristwatch, Pen/Pencil).  Ask the patient to 
name them. Give one point for each correct answer. 
1   “Repeat the phrase: ‘No ifs, ands, or buts.’” 
3   
“Take this paper in your right hand, fold it in half, and put it on the floor” 
(Give patient a blank piece of paper) 
1   “Please read this and do what it says.” (Written instruction is “Close your Eyes.”) 
1   
“Make up and write a sentence about anything.” (This sentence must contain a noun 
and a verb.) 
1   
“Please copy this picture.” (The examiner gives the patient a blank piece of paper and 
asks patient to draw the symbol below. All 10 angles must be present and the two 










30   TOTAL 
 
Cognitive Impairment 
suggested on MMSE? 
None (≥25/30)  Mild (19-24/30)  Moderate (10-18/30)  Severe (≤9/30)  
    
Unable to complete MMSE Y N 






3.7 Confusion Assessment Method (CAM) 
Evaluation Test Response (Please Circle) 
 
 Acute onset and fluctuating course BOX 1 
Is there evidence of an acute change in mental status from the 
Patient’s baseline? 
NO YES 
Did the (abnormal) behaviour fluctuate during the day, i.e. does it 
tend to come and go or increase and decrease in severity? 
NO YES 
 Inattention    
Did the patient have difficulty focusing attention, for example, being 




 Disorganised Thinking BOX 2 
Was the patient’s thinking disorganised or incoherent, such as 
rambling or irrelevant conversation, unclear or illogical flow of ideas, 
or unpredictable switching from subject to subject? 
NO YES 
 Altered Level Of Consciousness   
Overall, how would you rate this patient’s level of consciousness? 








Do any checks appear in the box above? 
Vigilant (Hyper alert) 
Lethargic (drowsy, easily aroused) 




















If all the items in BOX 1 are checked and at least one item in BOX 2 is check, 







 4.  Overall Summary Of Reference testing 
Delirium Suggested by DSM 4 Criteria? Y N 
Delirium Suggested by MMSE Assessment? Y N 
Delirium Suggested by CAM Assessment? Y N 





Please ensure that This Form is returned to Study Coordinator on day of completion  
If RACY form is in folder – Please collection this as well an return to Study coordinator 
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published	 online	 June	 28.	 http://dx.doi.org/10.1016/S0140-
6736(16)30388-9)
•	 To	 find	 reporting	 guidelines	 see:	 http://www.equator- 
network.org.
•	 We	encourage	authors	to	 share	any	additional	data,	preferably	
translated	 into	 English,	 that	would	 facilitate	 the	 replication	or	
further	analysis	of	their	work—eg,	the	raw	numbers	underlying	
their	analysis	or	the	code	for	any	modelling.	Mendeley	Data is a 
secure	online	repository	for	research	data,	permitting	archiving	
of	 any	file	 type	 and	 assigning	 a	 permanent	 and	unique	digital	
object	identifier	(DOI)	so	that	the	files	can	be	easily	referenced.	If	
authors	 wish	 to	 share	 their	 supporting	 data,	 and	 have	 not	
already	made	alternative	arrangements,	a	Mendeley	DOI	can	be	
referred	to	in	a	section	entitled	“Data	sharing”	at	the	end	of	the	
Methods	 section,	 ahead	 of	 “Role	 of	 the	 funding	 source”.	 If	
authors	have	already	deposited	their	data	in	another	repository,	
or	have	made	other	arrangements	for	data	to	be	shared	(eg,	by	
means	 of	 an	 adjudication	 process	 or	 contacting	 the	 authors),	
they	should	use	this	section	to	elaborate.
All Articles should, as relevant
•	 Be	up	to	3500	words	(4500	for	randomised	controlled	trials)	with	
30	references	(the	word	count	is	for	the	manuscript	text	only).
•	 Include	 an	 abstract	 (semistructured	 summary),	 with	 five	
paragraphs	 (Background,	 Methods,	 Findings,	 Interpretation,	
and	 Funding),	 not	 exceeding	 250	 words.	 Our	 electronic	
submission	system	will	ask	you	to	copy	and	paste	this	section	at	
the	“Submit	Abstract”	stage.
•	 For	 randomised	trials,	the	abstract	 should	adhere	to	CONSORT	
extensions:	abstracts	(see	Lancet 2008; 371:	281–83).
•	 When	reporting	Kaplan-Meier	survival	data,	at	each	timepoint,	
authors	must	 include	 numbers	 at	 risk,	 and	 are	 encouraged	 to	
include the number of censored patients.
•	 For	 intervention	 studies,	 the	 abstract	 should	 include	 the	
primary	outcome	expressed	as	the	difference	between	groups	
with	 a	 confidence	 interval	 on	 that	 difference	 (absolute	




non-proprietary	 name	 (rINN)	 for	drug	 names.	 Ensure	 that	 the	





Authors	 of	 microarray	 papers	 should	 include	 in	 their	
submission	 the	 information	 recommended	 by	 the	
MIAME	 guidelines. Authors should also submit their 
experimental	details	to	one	of	the	publicly	available	databases:	
ArrayExpress or GEO.
•	 Include	 any	 necessary	 additional	 data	 as	 part	 of	 your	
EES submission.
•	 All	 accepted	 Articles	 should	 include	 a	 link	 to	 the	 full	 study	
protocol published on the authors’ institutional website 
(see Lancet 2009; 373: 992 and Lancet 2010; 375: 348).
•	 We	 encourage	 researchers	 to	 enrol	women	 and	 ethnic	 groups	
into	clinical	trials	of	all	phases,	and	to	plan	to	analyse	data	by	sex	
and	by	race
•	 For	 all	 study	types,	we	 encourage	 correct	use	of	 the	terms	 sex	
(when	reporting	biological	factors)	and	gender	(when	reporting	
identity,	psychosocial,	or	cultural	factors).	Where	possible,	report	
the	 sex	 and/or	 gender	 of	 study	 participants,	 and	 describe	 the	
methods	used	to	determine	sex	and	gender.	Separate	reporting	
of	data	by	demographic	variables,	such	as	age	and	sex,	facilitates	
pooling	 of	 data	 for	 subgroups	 across	 studies	 and	 should	 be	
routine,	 unless	 inappropriate.	 Discuss	 the	 influence	 or	
association	 of	 variables,	 such	 as	 sex	 and/or	 gender,	 on	 your	
findings,	where	appropriate,	and	the	limitations	of	the	data.
Putting research into context
•	 All	 research	 papers	 (including	 systematic	 reviews/meta-analyses)	
submitted	to	any	journal	in	The Lancet	family	must	include	a	panel	
WHO’s International Clinical 
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putting	their	research	into	context	with	previous	work	in	the	format	
outlined below (see Lancet 2014; 384:	 2176–77,	 for	 the	 original	
rationale). This panel should not contain references. Editors will use 
this	 information	at	the	first	assessment	stage	and	peer	 reviewers	
will	be	specifically	asked	to	check	the	content	and	accuracy.	
•	 The	 Discussion	 section	 should	 contain	 a	 full	 description	 and	




Blue section (Comment, Correspondence) 
Editorial
•	 Editorials	are	the	voice	of	The Lancet HIV,	and	are	written	in-house	
by	the	journal’s	editorial-writing	team	and	signed	“The Lancet HIV”.
Comment
•	 This	 section	 contains	 Comments	 that	 accompany	 papers	
published in The Lancet HIV or	 on	 issues	 of	 wide-reaching	






•	 See Conflicts of Interest guidelines	for	comments.
Correspondence
•	 Letters	can	be	written	in	response	to	previous	content	published	
in The Lancet HIV.
•	 Letters	 for	 publication	 must	 reach	 us	 within	 4	 weeks	 of	
publication	of	 the	original	 item	and	 should	 be	no	 longer	 than	
400 words.
•	 Letters	 of	 general	 interest,	 unlinked	 to	 items	 published	 in	 the	
journal,	can	be	up	to	400	words	long.
•	 Correspondence	 is	 not	 usually	 peer	 reviewed,	 but	 we	 might	
invite	replies	from	the	authors	of	the	original	publication,	or	pass	
on letters to these authors.
•	 Only	 one	 table	 or	 figure	 is	 permitted,	 and	 there	 should	 be	 no	
more	than	five	references	and	five	authors.
•	 All	 accepted	 letters	 are	 edited.	 Proofs	 will	 be	 sent	 to	 authors	
before publication.
Corrections
•	 Any	substantial	error	 in	any	article	published	 in	The Lancet HIV 
should be corrected as soon as possible. Blame is not 
apportioned;	the	important	thing	is	to	set	the	record	straight.
•	 The	Lancet journals have a policy	for	types	of	errors	that	we	do	
and	do	not	 correct.	We	will	 always	 correct	any	error	affecting	
a	 non-proprietory	 drug	 name,	 dose,	 or	 unit,	 any	 numerical	





in	 Chinese,	 Portuguese,	 or	 Spanish	 may	 wish	 to	 use	 the	
Webshop	 (http://webshop.elsevier.com/languageservices) 
to	 provide	 an	 English	 translation	 of	 their	 manuscript	 for	
submission.
Title page
•	 A	 brief	 title,	 author	 name(s),	 preferred	 degree	 (one	 only),	
affiliation(s),	 and	 full	 address(es)	 of	 the	 authors	 must	 be	
included.	The	 name	 and	 address	 of	 the	 corresponding	 author	













•	 Do	 not	 use	 the	 automated	 features	 of	 your	 software,	 such	 as	
hyphenation,	 endnotes,	 headers,	 or	 footers	 (especially	 for	
references).	Please	use	page	numbering.
References
•	 Cite	 references	 in	 the	 text	 sequentially	 in	 the	
Vancouver	numbering	style,	as	a	superscripted	number	after	any	




an	 en	 rule.	 To	 create	 an	 en	 rule	 on	 a	 PC	 hold	 down	
CTRL	 key	 and	 minus	 sign	 on	 the	 number	 pad,	 on	 a	
Mac	ALT	hyphen.







corrections of errors see 
www.thelancet.com/for-
authors/forms#correction
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Added value of this study
Authors	should	describe	here	how	their	findings	add	value	to	
the	existing	evidence.
Implications of all the available evidence
Authors	should	state	the	implications	for	practice	or	policy	and	
future	research	of	their	study	combined	with	existing	evidence.
Research in context panels should not contain references; key 
studies mentioned here should be referenced in the main text.
Information for Authors 
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•	 References	in	tables,	figures,	and	panels	should	be	in	numerical	
order	according	to	where	the	item	is	cited	in	the	text.
•	 Here	 is	an	example	for	a	 journal	reference	(note	the	use	of	tab,	
bold,	italic,	and	the	en	rule):
“15[tab]Saito	 N,	 Ebara	 S,	 Ohotsuka	 K,	 Kumeta	




surname space initials comma
•	 If	there	are	seven	or	more	give	the	first	three	 in	the	same	way,	
followed	by	et	al.














Guidelines for supplementary material
All	 material	 should	 be	 submitted	 as	 one	 PDF	 (with	 numbered	
pages)	with	the	paper	and	will	be	peer	 reviewed.	Material	will	be	















•	 Recommended	 international	 non-proprietary	 name	 (rINN)	 is	
required 




•	 Numbered	 in	 order	 of	 mention	 in	 appendix	 and	 numbered	
separately	from	references	in	the	full	paper
Figures
•	 All	 images	 must	 have	 a	 minimum	 resolution	 of	 300	 dpi,	
width 107 mm.








interviewees,	 date	 of	 recording,	 and	 place	 of	 recording	 if	
relevant.
•	 Written	consent	from	all	parties	must	be	obtained	(see	also	the	







•	 Video	 material	 should	 be	 submitted	 in	 .mp4	 format	 with	
aspect	ratio	of	16:9,	and	be	no	larger	than	50	Mb
•	 We	 welcome	 your	 videos	 and	 invite	 you	 to	 submit	 any	
video	 material	 (reports,	 interviews,	 scans,	 imaging)	 for	
consideration in the online journal. Please ensure that 
all	 those	 featured	 in	 the	 video	 have	 given	 permission	 for	
publication (see also the previous section on Patient and 
other consents)
•	 All	video	files	can	be	submitted	alongside	your	article	in	EES





Journal	 Editors,	 The Lancet HIV	 does	 not	 regard	 results	 that	 are	





could jeopardise consideration of the manuscript.
Online publication
•	 The Lancet HIV	publishes	papers	online	as	they	become	ready.	You	
will	 be	 informed	 at	 least	 a	 week	 in	 advance	 of	 the	 Online	
publication date
How The Lancet HIV handles your paper 
Acknowledgment
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containing	 a	 reference	 number,	 which	 should	 be	 used	 in	 all	
future communications.
Peer review
•	 Every	Article	published	in	The Lancet HIV has been peer reviewed. 
Occasional	contributions	(eg,	Comments)	are	accepted	without	
peer review.
•	 On	submission	to	The Lancet HIV,	your	report	will	first	be	read	
by	 one	 or	 more	 of	 the	 journal’s	 staff	 of	 physicians	 and	
scientists. This is an important feature of our selection process 
and	 many	 papers	 will	 be	 turned	 away	 on	 the	 basis	 of	
in-house	 assessment	 alone.	 That	 decision	 will	 be	
communicated	quickly.
•	 Research	papers	selected	for	peer	review	are	sent	to	at	least	three	




might	 be	 referred	 back	 to	 authors	 for	 revision.	 This	 is	 an	
invitation	to	present	the	best	possible	paper	for	further	scrutiny	
by	the	journal;	it	is	not	an	acceptance.
•	 Authors	 should	 give	 priority	 to	 such	 revisions;	 the	 journal	will	
reciprocate	by	making	a	final	decision	quickly.




The Lancet journals and other Elsevier journals
•	 If	 your	 paper	 is	 rejected	 by	 The Lancet HIV,	we	might	 judge	
it suitable to pass to other editors in the Lancet-group	 for	
consideration or to editors of other relevant journals within 
Elsevier’s portfolio.
Appeals
•	 Sometimes	 editors	 make	 mistakes.	When	 we	 do,	 we	 like	 to	
hear	about	them.	If	an	author	believes	that	an	editor	has	made	
an	error	 in	declining	a	paper,	we	welcome	an	appeal.	 In	your	
appeal	 letter,	 which	 should	 be	 sent	 to	
thelancetHIV@lancet.com,	 please	 state	 why	 you	 think	 the	
decision	is	mistaken,	and	set	out	your	specific	responses	to	any	
peer reviewers’ comments if those seem to have been the 
main cause of rejection.




is	 likely	 that	 your	 paper	 will	 be	 substantially	 edited	 after	
acceptance	to	ensure	that	it	is	accurate,	clear,	and	understandable	
to a wide readership.
•	 All	figures	will	be	redrawn	into	The Lancet  style	by	our	in-house	
illustrators.
•	 You	 will	 receive	 a	 proof	 from	 an	 Assistant	 Editor.	 That	 proof	






paper	 entered	 into	 such	 a	 study,	 please	 let	 us	 know	 in	 your	
covering	 letter.	Your	 decision	 to	 take	 part	 or	 not	will	 have	 no	
effect	on	the	editorial	decision	on	your	paper.
Open access and funding
Open access
•	 The Lancet journals are committed to support authors in 
making	their	research	publicly	and	freely	available.	The	editors	
encourage	 all	 authors	 to	 post	 their	 peer-reviewed,	 accepted	
article	 on	 their	 personal	 or	 institutional	 websites	 any	 time	
after	 publication	 in	 print	 or	 online.	 Your	 document	 should	
indicate the article’s citation and a link to the published article 




Department	 of	 Health	 UK,	 UK	 Department	 of	 International	
Development	 (DFID),	 Dunhill	 Medical	 Trust,	 Motor	 Neuron	
Disease	Association,	 Parkinson’s	UK,	one	of	 the	UK	 Research	
Councils,	 Telethon	 Italy,	 or	Wellcome	Trust;	 for	 submissions	

















NIH Public Access Policy
•	 To	 allow	 authors	 to	 comply	with	the	National	 Institutes	of	
Health	 (NIH)	 Public	Access	 Policy,	we	will	 deposit	 accepted	
articles	(final	peer-reviewed	but	unedited	version)	reporting	
research	that	is	directly	funded	by	NIH	to	PubMed	Central	no	
later than 12 months after publication. For authors who are 
NIH	 employees	 (but	 not	 for	 those	with	 just	 NIH	 funding),	
any	 peer-reviewed	 accepted	 article	 of	 any	 type	 will	 be	
deposited	by	us	in	PubMed	Central	in	its	unedited	format	no	
later	than	12	months	after	publication.	All	Howard	Hughes	
Medical	 Institute	 scientists	 who	 are	 authors	 of	 accepted	
Articles can also have their accepted manuscripts deposited 
in	PubMed	Central	 if	 they	 complete	the	 relevant	 section	of	
the	Journal	Publishing	Agreement.
Information for Authors 
www.thelancet.com   September 2017 
Click	here	for	Elsevier’s	agreements	with	funding	bodies.
Copyright and reuse
Authors	 will	 be	 asked	 to	 sign	 a	 transfer	 of	 copyright	 agreement,	




other than The Lancet	 journals	 the	 right	 to	 make	 in	 any	 form	
facsimile copies of the version printed.
Gold	open	access	articles	are	published	under	Creative	Commons	
licensing,	 which	 enables	 authors	 to	 retain	 copyright	 while	
allowing	others	to	copy,	distribute,	and	make	some	uses	of	their	
work,	provided	full	credit	is	given	to	them	as	originators.	Authors	
will	be	offered	a	choice	of	two	 licences	 (CC	BY or CC	BY-NC-ND) 
depending	 on	 whether	 or	 not	 they	 wish	 to	 allow	 commercial	
reuse	of	their	work	and	whether	or	not	they	wish	to	allow	others	
to alter their work in the course of its reuse. Authors will be asked 
to	 sign	 an	 exclusive	 licence	 (or	 non-exclusive	 licence	 for	
government	 employees)	 to	 permit	 our	 publisher,	 Elsevier,	 to	
publish the work.






What happens after publication?
Press release
Press	 releases	 are	 issued	 by	 The Lancet	 journals’	 press	 office	 for	
selected	 content	 published	 in	 our	 journals.	You	will	 be	 advised	 in	
advance	if	your	paper	has	been	selected	for	press	release.	The Lancet 














The	 Lancet	 supports	 responsible	 sharing.	 We	 recognise	 that	
authors	want	to	share	their	papers	and	we	encourage	this.	Find	out	
how	you	can	share	your	paper	here
Press release 
http://www.thelancet.com/ 
press-room
For	Creative	Commons	licensing	
see http://creativecommons.
org/licenses/
Responsible sharing 
http://www.elsevier.com/
sharing-articles
